• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table E.7Sensitivity analysis showing incremental cost per QALY with a lower SSI treatment cost (£2,168)

StrategyQALYsCostIncremental QALYsIncremental costICER
No nasal decontamination615.59£185,093
Screen for S. aureus and treat identified carriers615.95£188,165N/A, dominatedN/A, dominatedN/A, dominated
Treat all patients with mupirocin616.16£186,6490.57£1,556£2,730

From: Appendix E, Cost-effectiveness of mupirocin nasal ointment to prevent surgical site infection caused by Staphylococcus aureus

Cover of Surgical Site Infection
Surgical Site Infection: Prevention and Treatment of Surgical Site Infection.
NICE Clinical Guidelines, No. 74.
National Collaborating Centre for Women's and Children's Health (UK).
London: RCOG Press; 2008 Oct.
Copyright © 2008, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.